2006 Pharmacology and Therapeutics Publications

Ailawadhi S, Sunga A, Rajput A, Yang GY, Smith J, Fakih M. Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology, 70: 49-53, 2006.

Alagbala AA, Johnson CS, Trump DL, Posner GH, Foster BA. Antitumor effects of two less-calcemic vitamin D analogs (paricalcitol & QW-1624F2-2) in squamous cell carcinoma (SCC) cells. Oncology 70: 483-492, 2006.

Alagbala AA, McRiner AJ, Borstnik K, Labonte T, Chang W, D’Angelo JG, Posner GH, Foster BA. Biological mechanisms of action of novel C-10 non-acetal trioxane dimers in prostate cancer cell lines. J Med Chem, 49: 7836-7842, 2006.

Azrak RG, Frank CL, Ling X, Slocum HK, Li F, Foster BA, Rustum YM. The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Mol Cancer Ther, 5: 2540-2548, 2006.

Bellnier DA, Greco WR, Nava H, Loewen GM, Oseroff AR, Dougherty TJ. Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy. Cancer Chemother. Pharmacol., 57: 40-45, 2006.

Borbely AA, Murvai M, Konya J, Beck Z, Gergely L, Li F, Veress G. Effects of human papillomavirus (HPV) type 16 oncoproteins on survivin gene expression. J. Gen. Virol., 87(Pt2): 287-294, 2006.

Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG, Javle MM. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol, 13: 933-939, 2006.

Chanan-Khan AA, Miller KC, DiMicelli L, Lawrence D, Padmanabhan-Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spanner D, Byrne C, Hernandez-Illizaliturri F, Chrystal C, Czuczman MW. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Results of a phase II study J. Clin. Oncol, 24: 5342-5349, 2006.

Chanan-Khan A , Porter CW. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol, 7: 480-488, 2006.

Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL. Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res, 66: 8565-8573, 2006.

Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, Lewis R, Wiederhold N, Holland SM, Petraitiene R, Walsh TJ, Segal BH. Effect of Amphotericin B and Micafungin Combination on Survival, Histopathology, and Fungal Burden in Experimental Aspergillosis in the p47phox-/- Mouse Model of Chronic Granulomatous Disease. Antimicrob Agents Chemother., 50: 422-427, 2006.

Dziegielewska B, Beerman TA, Bianco PR. Inhibition of RecBCD Enzyme by Antineoplastic DNA Alkylating Agents. J Mol Biol, 361: 898-919, 2006.

Esteve P-O, Chin HG, Smallwood A, Gangisetty O, Karpf AR, Carey MF, Pradhan S. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during DNA replication. Genes and Development 20: 3089-3103, 2006.

Ewens A, Luo L, Berleth E, Alderfer J, Wollman R, Hafeez BB, Kanter P, Mihich E, Ehrke MJ. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res, 66: 5419-5426, 2006.

Fakih MG, Rajput A, Yang GY, Pendyala L, Toth K, Smith JL, Lawrence DD, Rustum YM. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys, 65: 1462-1470, 2006.

Flynn G, Chung I, Yu WD, Romano M, Modzelewski RA, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncology, 70: 447-457, 2006.

Gangjee A, Yang J, McGuire JJ, Kisliuk RL. Synthesis and evaluation of classical 2, 4-diamino-5-substituted-furo[2,3-d]pyrimidine and 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates. Bioorg. Med. Chem. Lett., 14: 8590-8598, 2006.

Gangjee A, Jain HD, Phan J, Lin X, Song X, McGuire JJ, Kisliuk RL. Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1). J Med Chem, 49: 1055-1065, 2006.

Gangjee A, Yang J, McGuire JJ, Kisliuk RL. Synthesis and evaluation of classical 2, 4-diamino-5-substituted-furo[2,3-d]pyrimidine and 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates. Bioorg. Med. Chem. Lett., 14:8590-8, 2006.

Gerhauser C, Bartsch H, Crowell J, De Flora S, D'Incalci M, Dittrich C, Frank N, Mihich E, Steffen C, Tortora G, Gescher A. Development of novel cancer chemopreventive agents in Europe - Neglected Cinderella or rising phoenix? ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005. Eur.J.Cancer [A], 42: 1338-1343, 2006.

Godert AM, Angelino N, Woloszynska-Read A, Morey SR, James SR, Karpf AR, Sufrin JR. An improved synthesis of psammaplin A. Bioorg Med Chem Lett, 16: 3330-3333, 2006.

Goodrich DW. The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene, 25: 5233-5243, 2006.

Hizli AA, Black AR, Pysz MA, Black JD. Protein kinase C alpha signaling inhibits cyclin D1 translation in intestinal epithelial cells. J Biol Chem, 281: 14596-14603, 2006.

James SR, Link P, Karpf AR. Epigenetic regulation of X-linked cancer/germ-line antigen genes by DNMT1 and DNMT3b. Oncogene, 25: 6975-6985, 2006.

Javle MM, Yu J, Khoury T, Chadha KC, Iyer R, Foster J, Kuvshinoff B, Gibbs JF, Geradts J, Black JD, Brattain MG. AKT expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol, 21: 1744-1751, 2006.

Johnson CS, Muindi JR, Hershberger PA, Trump DL. The antitumor efficacy of calcitriol: preclinical studies. Anticancer Res, 26: 2543-2549, 2006.

Karpf AR. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 1: 116-120, 2006.

Kennedy DR , Beerman TA. The radiomimetic enediyne C-1027 induces unusual DNA damage responses to double-strand breaks. Biochemistry, 45: 3747-3754, 2006.

Knights CD, Catania J, Giovanni SD, Muratoglu S, Perez R, Swartzbeck A, Quong AA, Zhang X, Beerman T, Pestell RG, Avantaggiati ML. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol, 173: 533-544, 2006.

Kuznetsova LV, Chen J, Sun L, Wu X, Pepe A, Veith JM, Bernacki RJ, Ojima I. Synthesis and evaluation of novel fatty acid 2nd generation taxoid conjugate as promising anticancer agents. Bioorg Med Chem Lett., 16: 974-977, 2006.

Lauffart B, Dimatteo A, Vaughan MM, Cincotta MA, Black JD, Still IH. Temporal and spatial expression of TACC1 in the mouse and human. Dev Dyn, 235: 1638-1647, 2006.

Lee SO, Chun JY, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate, 66: 1070-1075, 2006.

Levin B, Barthel JS, Burt RW, David DS, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton S, Kohlmann W, Ludwig KA, Lynch PM, Marino C, Martin EW, Jr., Mayer RJ, Pasche B, Pirruccello SJ, Rajput A, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D, Winawer SJ. Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw, 4: 384-420, 2006.

Li F , Ling X. Survivin study: An update of "What is the next wave?" J Cell Physiol, 208: 476-486, 2006.

Li F , Brattain MG. Role of the Survivin gene in pathophysiology. Am J Pathol, 169: 1-11, 2006.

Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SA, Karuppayil SM, Rajasekaran AK, Das GM. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem, 281: 9837-9840, 2006.

Luo W, Wang X, Kageshita T, Wakasugi S, Karpf AR, Ferrone S. Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene, 25: 2873-2884, 2006.

Ma Y, Yu WD, Kong RX, Trump DL, Johnson CS. Role of Nongenomic Activation of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase 1/2 Pathways in 1,25D3-Mediated Apoptosis in Squamous Cell Carcinoma Cells. Cancer Res, 66: 8131-8138, 2006.

Mason DX, Keppler D, Zhang J, Jackson TJ, Seger YR, Matsui S, Abreo F, Cowell JK, Hannon GJ, Lowe SW, Lin AW. Defined genetic events associated with the spontaneous in vitro transformation of E1A/Ras-expressing human IMR90 fibroblasts. Carcinogenesis, 27: 350-359, 2006.

McGuire JJ, Haile WH, Yeh CC. 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism. Cancer Res, 66: 3836-3844, 2006.

Mihich E. Commentary on the IV Sao Paulo Research Conference Cancer Today: From Molecular Biology to Treatment. Brazilian Journal of Medical and Biological Research, 39: 1263-1270, 2006.

Morey SR, Smiraglia DJ, James SR, Yu J, Moser MT, Foster BA, Karpf AR. DNA methylation pathway alterations in an autochthonous murine model of prostate cancer. Cancer Res, 66: 11659-11667, 2006.

Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC. Stat3 activation of NF-kappaB p100 processing involves CBP/p300-mediated acetylation. Proc.Natl.Acad.Sci.USA, 103: 7264-7269, 2006.

Rai K, Nadauld LD, Chidester S, Manos EJ, James SR, Karpf AR, Cairns BR, Jones DA. Zebra Fish Dnmt1 and Suv39h1 regulate organ-specific terminal differentiation during development. Mol Cell Biol 126: 7077-7085, 2006.

Sawhney RS, Cookson MM, Omar Y, Hauser J, Brattain MG. Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway. J Biol Chem, 281: 8497-8510, 2006.

Spaulding B, Pan D, Ghadersohi A, Nielsen G, Jensen S, Gellert F, Ling X, Black A, Li F. Characterization of the 12C4 survivin monoclonal antibody and insight into the expression of survivin in human adult tissues. Histopathology 49: 622-633, 2006.

Spengler ML , Brattain MG. Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription. J Biol Chem, 281: 5567-5574, 2006.

Sun H, Chang Y, Schweers B, Dyer MA, Zhang X, Hayward S, Goodrich DW. An E2F-binding deficient Rb1 protein partially rescues developmental defects associated with Rb1 nullizygosity. Mol Cell Biol., 26: 1527-1537, 2006.

Thomas JL, Ghosh D, Scaccia LA, Kacsoh B. Inhibitors of steroid sulfatase, 3β-hydroxysteroid dehydrogenase type 1 or aromatase block the growth of our genetically engineered human breast tumor MCF-7 cell line. J. Endocrinology, (In press).

Wang X, Chang Y, Li Y, Zhang X, Goodrich DW. Thoc1/Hpr1/p84 is essential for early embryonic development in the mouse. Mol Cell Biol, 26: 4362-4367, 2006.

Wang R , Brattain MG. AKT can be activated in the nucleus. Cell Signal, 18: 1722-1731, 2006.

Weinberg R , Mihich E. Meeting Report: Eighteenth Annual Pezcoller Symposium: Tumor Microenvironment: Hetertypic Interactions, Trento, Italy, June 27-29, 2006. Cancer Res, 66: 11550-11553, 2006.

Yin MB, Li ZR, Toth K, Cao S, Durrani FA, Hapke G, Bhattacharya A, Azrak RG, Frank C, Rustum YM. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis. Oncogene, 25: 2509-2519, 2006.

Yin S , Goodrich DW. Combination gene therapy with p53 and Thoc1/p84 is more effective than either single agent in an animal model of human pancreatic adenocarcinoma. Int J Oncol, 28: 781-785, 2006.

Zaenker KS, Mustacchi G, Mihich E. Molecular targets of cancer chemotherapy. Cancer Chemother Pharmacol, 58: 279-282, 2006.

Zhang M, Yang J, Li F. Transcriptional and post-transcriptional controls of survivin in cancer cells: Novel approaches for cancer treatment. J. Exp. Clin. Cancer Res, 25: 391-402, 2006.

Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res, 66: 404-411, 2006.

Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P, Nikitin AY. Synergy of p53 and Rb Deficiency in a Conditional Mouse Model for Metastatic Prostate Cancer. Cancer Res, 66: 7889-7898, 2006.

Zu K, Bihani T, Lin A, Park YM, Mori K, Ip C. Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells. Oncogene, 25: 546-554, 2006.